KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Inventory (2016 - 2025)

Acadia Pharmaceuticals has reported Inventory over the past 10 years, most recently at $34.7 million for Q4 2025.

  • Quarterly results put Inventory at $34.7 million for Q4 2025, up 57.96% from a year ago — trailing twelve months through Dec 2025 was $34.7 million (up 57.96% YoY), and the annual figure for FY2025 was $34.7 million, up 57.96%.
  • Inventory for Q4 2025 was $34.7 million at Acadia Pharmaceuticals, up from $29.1 million in the prior quarter.
  • Over the last five years, Inventory for ACAD hit a ceiling of $71.5 million in Q2 2024 and a floor of $5.8 million in Q3 2022.
  • Median Inventory over the past 5 years was $17.6 million (2021), compared with a mean of $23.5 million.
  • Biggest five-year swings in Inventory: surged 916.18% in 2024 and later plummeted 63.48% in 2025.
  • Acadia Pharmaceuticals' Inventory stood at $7.9 million in 2021, then fell by 15.8% to $6.6 million in 2022, then surged by 439.77% to $35.8 million in 2023, then crashed by 38.72% to $21.9 million in 2024, then skyrocketed by 57.96% to $34.7 million in 2025.
  • The last three reported values for Inventory were $34.7 million (Q4 2025), $29.1 million (Q3 2025), and $26.1 million (Q2 2025) per Business Quant data.